Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michelle Price

Nurse Practitioner, Adult Health Charleston, SC Nurse Practitioner

NPI 1184117889 CMS profile 10849196

2270 Ashley Crossing Dr Ste 150, Charleston, SC 29414

Open in the dashboard

General payments

$12,719

703 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Price of Charleston, SC is reported in the CMS Open Payments database as having received $12,719 across 703 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,395 117
2024 General $2,234 118
2023 General $3,170 157
2022 General $2,887 180
2021 General $2,033 131

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Price
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Michelle Price were reported at $2,395. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Michelle Price Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,033 $138 $43–$438 $132
2022 $2,887 $165 $54–$494 $149
2023 $3,170 $178 $61–$549 $160
2024 $2,234 $186 $62–$575 $164
2025 $2,395 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,332 94 payments
  2. Lilly USA, LLC $1,217 56 payments
  3. Novo Nordisk Inc $1,053 79 payments
  4. AstraZeneca Pharmaceuticals LP $1,043 41 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $738 35 payments
  6. Pfizer Inc. $619 32 payments
  7. Amgen Inc. $451 35 payments
  8. GlaxoSmithKline, LLC. $449 24 payments
  9. Janssen Pharmaceuticals, Inc $378 15 payments
  10. Esperion Therapeutics, Inc. $329 20 payments
  11. Other $5,109 272 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,699 701 payments
  2. Education $20 2 payments
Products named General payments · program years 2021–2025
  1. Kerendia $738 35 payments
  2. Ozempic $702 60 payments
  3. RYBELSUS $702 60 payments
  4. FARXIGA $669 24 payments
  5. MOUNJARO $658 28 payments
  6. VRAYLAR $525 39 payments
  7. UBRELVY $522 35 payments
  8. GEMTESA $455 22 payments
  9. ELIQUIS $381 18 payments
  10. XARELTO $378 15 payments
  11. Other $10,573 590 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 100 drugs

Part D claims

3,845

Median for Nurse Practitioner: 389

Drug cost

$505,875

Median for Nurse Practitioner: $21,885

Branded share of claims

23.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 95 $143,193
Farxiga Dapagliflozin Propanediol Brand 74 $83,160
Mounjaro Tirzepatide Brand 49 $61,490
Rybelsus Semaglutide Brand 12 $31,780
Januvia Sitagliptin Phosphate Brand 29 $30,795
Eliquis Apixaban Brand 27 $29,588
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 26 $27,232
Jardiance Empagliflozin Brand 19 $25,183
Trulicity Dulaglutide Brand 11 $13,562
Symbicort Budesonide/Formoterol Fumarate Brand 19 $8,724

The 10 drugs with the highest cost, of 100 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$132,961

Of which drugs: $7,477

Medicare patients

525

Average age 75

Services billed

4,248

403 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Osteoporosis 34%
Depression 32%
Diabetes 29%
Chronic kidney disease 27%
Ischemic heart disease 22%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 46 46 $3,682
Sarscv2 vac 30mcg trs-suc im 91320 Office 12 12 $1,681
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 17 257 $48
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 18 43 $40
Injection, ketorolac tromethamine, per 15 mg J1885 Office 29 43 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 38 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
$215 49 —
AIRSUPRA
$157 — —
FARXIGA
$129 74 —
TRELEGY ELLIPTA
$122 26 —
Kerendia
$103 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 38 with Patron

Records

703 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record